PyroGenesis Announces 2024 First Quarter Results
MONTREAL, May 14, 2024 -- PyroGenesis Canada Inc. , a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are...
Stay updated with breaking news from Development Rd Expenses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MONTREAL, May 14, 2024 -- PyroGenesis Canada Inc. , a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are...
– Achieved $21.0 million in OGSIVEO® net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – ...
02.05.2024 - - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 ...
HARMONi and HARMONi-3 Enrollment Continues Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with...
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Quarter 2024 Financial Results 29.04.2024 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, April 29, 2024 MorphoSys AG Reports First Quarter 20...